In patients with eosinophilic granulomatosis with polyangiitis in remission phase and persisting severe steroid-dependent asthma, mepolizumab 100 mg/4 wk prevents vasculitis relapse and maintains asthma control. An “asthma-tailored” dose may be considered in the maintenance phase of eosinophilic granulomatosis with polyangiitis as a steroid/immunosuppressive-sparing agent.

Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase

Caminati, Marco;Crisafulli, Ernesto;Lunardi, Claudio;Micheletto, Claudio;Festi, Giuliana;Maule, Matteo;Giollo, Alessandro;Orsolini, Giovanni;Senna, Gianenrico
2021-01-01

Abstract

In patients with eosinophilic granulomatosis with polyangiitis in remission phase and persisting severe steroid-dependent asthma, mepolizumab 100 mg/4 wk prevents vasculitis relapse and maintains asthma control. An “asthma-tailored” dose may be considered in the maintenance phase of eosinophilic granulomatosis with polyangiitis as a steroid/immunosuppressive-sparing agent.
2021
Mepolizumab, severe asthma, EGPA
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/1027040
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 21
social impact